Nektar Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Nektar Therapeutics (NKTR) Tops Q4 EPS by 4c, Revenues Beat
February 27, 2020 4:48 PM ESTNektar Therapeutics (NASDAQ: NKTR) reported Q4 EPS of ($0.64), $0.04 better than the analyst estimate of ($0.68). Revenue for the quarter came in at $33.86 million versus the consensus estimate of $26.93 million.
"Nektar's progress over the past year has established a strong foundation for growth, with a robust portfolio of clinical-stage immuno-oncology and immunology... More
